IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Boston Family Office LLC

Boston Family Office LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% during the fourth quarter, HoldingsChannel reports. The firm owned 27,381 shares of the company’s stock after purchasing an additional 473 shares during the quarter. Boston Family Office LLC’s holdings in IDEXX Laboratories were worth $11,320,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in IDXX. Geode Capital Management LLC boosted its position in IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock valued at $948,279,000 after buying an additional 37,734 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of IDEXX Laboratories by 17.0% in the 4th quarter. National Bank of Canada FI now owns 73,028 shares of the company’s stock valued at $30,193,000 after acquiring an additional 10,592 shares during the last quarter. B. Metzler seel. Sohn & Co. AG increased its stake in shares of IDEXX Laboratories by 57.6% in the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 14,557 shares of the company’s stock worth $6,018,000 after acquiring an additional 5,322 shares during the period. Wellington Management Group LLP lifted its position in IDEXX Laboratories by 161.2% during the fourth quarter. Wellington Management Group LLP now owns 195,369 shares of the company’s stock valued at $80,773,000 after purchasing an additional 120,558 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in IDEXX Laboratories by 6.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 142,192 shares of the company’s stock worth $58,788,000 after purchasing an additional 8,617 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.0 %

Shares of NASDAQ IDXX opened at $419.95 on Tuesday. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company’s 50-day simple moving average is $437.08 and its 200-day simple moving average is $442.03. The firm has a market cap of $34.04 billion, a price-to-earnings ratio of 39.36, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, March 25th. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.